{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T04:41:45Z","timestamp":1759380105960,"version":"build-2065373602"},"reference-count":52,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T00:00:00Z","timestamp":1759363200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Multiple Sclerosis (MS) is an immune-mediated, demyelinating disease of the central nervous system. Although psoriasis and psoriasiform dermatitis are reported in MS patients, the prevalence of the diseases is uncertain globally and unstudied in Australia. This study aims to determine the frequency of psoriasis in a clinic-based cohort of Australian MS patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A survey was conducted on 204 consecutive MS patients aged 18 and over who attended a tertiary MS clinic in Northern Sydney from July 2018 to December 2022.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 204 patients were examined, comprising 137 female (67.2%) and 67 male (32.8%). The mean age was 48.8 years (SD = 13.6). Psoriasis was identified in 13.7% (28\/204; 95% CI: 9.63% to 19.20%).<\/jats:p><\/jats:sec><jats:sec><jats:title>Discussion<\/jats:title><jats:p>The frequency of psoriasis in MS is high and may be underestimated, given that many more patients have symptoms without signs. This implies an immunopathological link between the two conditions and is worthy of further study.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fneur.2025.1663015","type":"journal-article","created":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T04:20:33Z","timestamp":1759378833000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["The frequency of psoriasis in Australian multiple sclerosis patients"],"prefix":"10.3389","volume":"16","author":[{"given":"Varitsara","family":"Mangkorntongsakul","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ariadna","family":"Fontes-Villalba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Turlough","family":"Montague","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olivia","family":"Charlton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chun-Ting Justin","family":"Kwong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helen Marie","family":"McGuire","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Venkatesha","family":"Venkatesha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Geoffrey","family":"Herkes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saxon","family":"Smith","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Parratt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,10,2]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1212\/WNL.0b013e3181cec45c","article-title":"MRI criteria for MS in patients with clinically isolated syndromes","volume":"74","author":"Montalban","year":"2010","journal-title":"Neurology."},{"key":"B2","doi-asserted-by":"publisher","first-page":"1622","DOI":"10.1016\/S0140-6736(18)30481-1","article-title":"Multiple sclerosis","volume":"391","author":"Thompson","year":"2018","journal-title":"Lancet."},{"key":"B3","doi-asserted-by":"publisher","first-page":"760","DOI":"10.3389\/fimmu.2020.00760","article-title":"B and T cells driving multiple sclerosis: identity, mechanisms and potential triggers","volume":"11","author":"Van Langelaar","year":"2020","journal-title":"Front Immunol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1002\/ana.25927","article-title":"Role of B cells in multiple sclerosis and related disorders","volume":"89","author":"Comi","year":"2021","journal-title":"Ann Neurol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1038\/s41423-020-00618-z","article-title":"Paving the way towards an effective treatment for multiple sclerosis: advances in cell therapy","volume":"18","author":"Mansilla","year":"2021","journal-title":"Cell Mol Immunol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1007\/s13760-012-0061-x","article-title":"Self-tolerance in multiple sclerosis","volume":"112","author":"Gonsette","year":"2012","journal-title":"Acta Neurol Belg."},{"key":"B7","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.ejphar.2015.03.042","article-title":"Animal models of multiple sclerosis","volume":"759","author":"Procaccini","year":"2015","journal-title":"Eur J Pharmacol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1038\/s41572-018-0041-4","article-title":"Multiple sclerosis","volume":"4","author":"Filippi","year":"2018","journal-title":"Nat Rev Dis Primers."},{"key":"B9","doi-asserted-by":"publisher","first-page":"2426","DOI":"10.1093\/brain\/awx185","article-title":"Towards personalized therapy for multiple sclerosis: prediction of individual treatment response","volume":"140","author":"Kalincik","year":"2017","journal-title":"Brain."},{"key":"B10","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1038\/jid.2012.339","article-title":"Global epidemiology of psoriasis: a systematic review of incidence and prevalence","volume":"133","author":"Parisi","year":"2013","journal-title":"J Invest Dermatol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1007\/s40257-018-0399-9","article-title":"Association of multiple sclerosis with psoriasis: a systematic review and meta-analysis of observational studies","volume":"20","author":"Liu","year":"2019","journal-title":"Am J Clin Dermatol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1016\/j.jaad.2010.11.046","article-title":"Psoriasis and cardiovascular risk factors: a case-control study on inpatients comparing psoriasis to dermatitis","volume":"66","author":"Shapiro","year":"2012","journal-title":"J Am Acad Dermatol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1016\/j.amjmed.2009.08.022","article-title":"Coronary heart disease and stroke risk in patients with psoriasis: retrospective analysis","volume":"123","author":"Kimball","year":"2010","journal-title":"Am J Med."},{"key":"B14","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1016\/j.jdermsci.2015.03.012","article-title":"Risk of incident chronic kidney disease and end-stage renal disease in patients with psoriasis: a nationwide population-based cohort study","volume":"78","author":"Chi","year":"2015","journal-title":"J Dermatol Sci."},{"key":"B15","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1001\/jamaophthalmol.2017.0569","article-title":"Risk of uveitis among people with psoriasis: a nationwide cohort study","volume":"135","author":"Chi","year":"2017","journal-title":"JAMA Ophthalmol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1586\/14737167.2014.914437","article-title":"Quality of life in psoriasis patients","volume":"14","author":"Augustin","year":"2014","journal-title":"Expert Rev Pharmacoecon Outcomes Res."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1001\/archderm.143.12.1493","article-title":"The risk of mortality in patients with psoriasis: results from a population-based study","volume":"143","author":"Gelfand","year":"2007","journal-title":"Arch Dermatol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/j.1468-3083.2011.04410.x","article-title":"The concept of psoriasis as a systemic inflammation: implications for disease management","volume":"26","author":"Reich","year":"2012","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1191\/1352458504ms1087oa","article-title":"A prospective study of conditions associated with multiple sclerosis in a cohort of 658 consecutive outpatients attending a multiple sclerosis clinic","volume":"10","author":"Edwards","year":"2004","journal-title":"Mult Scler J."},{"key":"B20","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1016\/S1474-4422(06)70552-X","article-title":"Clustering of autoimmune diseases in families with a high-risk for multiple sclerosis: a descriptive study","volume":"5","author":"Barcellos","year":"2006","journal-title":"Lancet Neurol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1177\/1352458514564490","article-title":"A systematic review of the incidence and prevalence of autoimmune disease in multiple sclerosis","volume":"21","author":"Marrie","year":"2015","journal-title":"Mult Scler J."},{"key":"B22","doi-asserted-by":"publisher","first-page":"81","DOI":"10.2147\/PTT.S186637","article-title":"A narrative review of psoriasis and multiple sclerosis: links and risks","volume":"9","author":"Silfvast-Kaiser","year":"2019","journal-title":"Psoriasis: Targets Ther."},{"key":"B23","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1002\/ana.26672","article-title":"Shared genetic risk factors for multiple sclerosis\/psoriasis suggest involvement of interleukin-17 and Janus Kinase\u2013signal transducers and activators of transcription signaling","volume":"94","author":"Patrick","year":"2023","journal-title":"Ann Neurol."},{"key":"B24","first-page":"81","article-title":"A narrative review of psoriasis and multiple sclerosis: links and risks","volume":"2019","author":"Silfvast-Kaiser","year":"","journal-title":"Psoriasis: Targets Ther"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.m1590","article-title":"National, regional, and worldwide epidemiology of psoriasis: systematic analysis and modelling study","author":"Parisi","year":"","journal-title":"BMJ"},{"key":"B26","doi-asserted-by":"publisher","first-page":"106425","DOI":"10.1016\/j.msard.2025.106425","article-title":"Seronegative spondyloarthritis as a complication of anti-CD20 monoclonal antibody treatment in multiple sclerosis","volume":"99","author":"Montague","year":"2025","journal-title":"Mult Scler Relat Disord."},{"key":"B27","doi-asserted-by":"publisher","first-page":"2106","DOI":"10.1038\/s41598-021-81588-8","article-title":"Suppression of IL-23-mediated psoriasis-like inflammation by regulatory B cells","volume":"11","author":"Mizumaki","year":"2021","journal-title":"Sci Rep."},{"key":"B28","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1002\/acr.21848","article-title":"Leflunomide in psoriatic arthritis: results from a large European prospective observational study","volume":"65","author":"Behrens","year":"2013","journal-title":"Arthritis Care Res."},{"key":"B29","doi-asserted-by":"publisher","first-page":"1604","DOI":"10.1002\/art.1780381112","article-title":"Oral 2-chlorodeoxyadenosine in psoriatic","volume":"38","author":"Eibschutz","year":"1995","journal-title":"Arthritis Rheum."},{"key":"B30","first-page":"575","article-title":"Multiple sclerosis and psoriasis","volume":"42","author":"Cendrowski","year":"1989","journal-title":"Wiad Lek."},{"key":"B31","doi-asserted-by":"publisher","first-page":"e397","DOI":"10.1111\/jdv.14205","article-title":"Multiple sclerosis association with psoriasis: a large US population, single centre, retrospective cross-sectional study","volume":"31","author":"Guido","year":"2017","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"2055","DOI":"10.1111\/jdv.14403","article-title":"Psoriasis comorbidity affects multiple sclerosis neurological progression: a retrospective case\u2013control analysis","volume":"31","author":"Miron","year":"2017","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1016\/j.jns.2014.01.003","article-title":"Multiple sclerosis is associated with psoriasis. A case\u2013control study","volume":"338","author":"Fellner","year":"2014","journal-title":"J Neurol Sci."},{"key":"B34","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1054\/jocn.2000.0693","article-title":"The occurrence of autoimmune diseases in patients with multiple sclerosis and their families","volume":"7","author":"Henderson","year":"2000","journal-title":"J Clin Neurosci."},{"key":"B35","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1111\/j.1600-0404.1996.tb00004.x","article-title":"Multiple sclerosis and chronic inflammatory diseases a case-control study","volume":"93","author":"Midgard","year":"1996","journal-title":"Acta Neurol Scand."},{"key":"B36","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1038\/JID.2015.350","article-title":"Risk of multiple sclerosis in patients with psoriasis: a Danish nationwide cohort study","volume":"136","author":"Egeberg","year":"2016","journal-title":"J Invest Dermatol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1111\/ene.13819","article-title":"Multiple sclerosis\u2013a review","volume":"26","author":"Dobson","year":"2019","journal-title":"Eur J Neurol."},{"key":"B38","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/s41572-025-00630-5","article-title":"Psoriasis","volume":"11","author":"Armstrong","year":"2025","journal-title":"Nat Rev Dis Primers."},{"key":"B39","first-page":"S220","article-title":"Implications for multiple sclerosis in the era of the affordable care act: a clinical overview","volume":"20","author":"Maroney","year":"2014","journal-title":"Am J Manag Care."},{"key":"B40","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1136\/jnnp.2011.240432","article-title":"Latitude is significantly associated with the prevalence of multiple sclerosis: a meta-analysis","volume":"82","author":"Simpson","year":"2011","journal-title":"J Neurol Neurosurg Psychiatry."},{"key":"B41","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1177\/1352458516686847","article-title":"Environmental modifiable risk factors for multiple sclerosis: report from the 2016 ECTRIMS focused workshop","volume":"24","author":"Amato","year":"2018","journal-title":"Mult Scler J."},{"key":"B42","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1097\/WCO.0000000000000205","article-title":"Advances in the immunopathogenesis of multiple sclerosis","volume":"28","author":"Yadav","year":"2015","journal-title":"Curr Opin Neurol."},{"key":"B43","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.cellimm.2018.09.001","article-title":"IL-17 and limits of success","volume":"339","author":"Omidian","year":"2019","journal-title":"Cell Immunol."},{"key":"B44","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1007\/s12016-018-8702-3","article-title":"The immunologic role of IL-17 in psoriasis and psoriatic arthritis pathogenesis","volume":"55","author":"Blauvelt","year":"2018","journal-title":"Clin Rev Allergy Immunol."},{"key":"B45","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1007\/s00415-016-8128-x","article-title":"Activity of secukinumab, an anti-IL-17A antibody, on brain lesions in RRMS: results from a randomized, proof-of-concept study","volume":"263","author":"Havrdov\u00e1","year":"2016","journal-title":"J Neurol."},{"key":"B46","doi-asserted-by":"publisher","first-page":"146","DOI":"10.2353\/ajpath.2008.070690","article-title":"Interleukin-17 production in central nervous system-infiltrating T cells and glial cells is associated with active disease in multiple sclerosis","volume":"172","author":"Tzartos","year":"2008","journal-title":"Am J Pathol."},{"key":"B47","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1016\/j.immuni.2020.01.002","article-title":"Interleukin-17A serves a priming role in autoimmunity by recruiting IL-1\u03b2-producing myeloid cells that promote pathogenic T cells","volume":"52","author":"McGinley","year":"2020","journal-title":"Immunity"},{"key":"B48","doi-asserted-by":"publisher","first-page":"CD011076","DOI":"10.1002\/14651858.CD011076.pub2","article-title":"Dimethyl fumarate for multiple sclerosis","volume":"2015","author":"Xu","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"key":"B49","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/jdv.15218","article-title":"Clinical use of dimethyl fumarate in moderate-to-severe plaque-type psoriasis: a European expert consensus","volume":"32","author":"Mrowietz","year":"2018","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"B50","doi-asserted-by":"publisher","first-page":"151","DOI":"10.2310\/7750.2010.09063","article-title":"Psoriasis and multiple sclerosis: is there a link?","volume":"14","author":"Kwok","year":"2010","journal-title":"J Cutan Med Surg."},{"key":"B51","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1007\/s10072-009-0184-x","article-title":"Psoriasis during interferon beta treatment for multiple sclerosis","volume":"31","author":"La Mantia","year":"2010","journal-title":"Neurol Sci."},{"key":"B52","first-page":"97","article-title":"Focus: skin: current developments in the immunology of psoriasis","volume":"93","author":"Gr\u00e4n","year":"2020","journal-title":"Yale J Biol Med."}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2025.1663015\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T04:20:37Z","timestamp":1759378837000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2025.1663015\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,2]]},"references-count":52,"alternative-id":["10.3389\/fneur.2025.1663015"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2025.1663015","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,2]]},"article-number":"1663015"}}